^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    miRisk

    Company:
    Hummingbird Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    miRisk is a blood-based microRNA panel that predicts immunotherapy response in stage IV NSCLC. Has significant and improved survival prediction. It gives significant and immediate value for patients
    Cancer:
    Non Small Cell Lung Cancer